Form 4: Nurix Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., sold 4,111 shares of common stock on August 4, 2026.
Summary
- Open-market sale: disposed of 1,500 Common Stock at $23.87 ($35,803) on August 4, 2026; holds 119,838 after (Direct).
- Open-market sale: disposed of 2,611 Common Stock at $24.64 ($64,339) on August 4, 2026; holds 117,227 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $100,142 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Gwenn Hansen — Officer (Chief Scientific Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-04 | Open-market sale | Common Stock | 1,500 | $24 | $35.8K | 119,838 |
| 2026-08-04 | Open-market sale | Common Stock | 2,611 | $25 | $64.3K | 117,227 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-04 | Open-market sale (1,500 shares) |
| 2026-08-04 | Open-market sale (2,611 shares) |
Keywords
insider transaction, Form 4, NRIX, Nurix Therapeutics, Inc., bearish, Gwenn Hansen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.